Zimmer Biomet announces FDA de nova classification grant for smart knee implant
Zimmer Biomet Holdings Inc. and Canary Medical announced FDA de novo classification grant and authorization to market the tibial extension for the Persona IQ, a smart knee implant for total knee replacement surgery.
According to a company press release, Persona IQ combines previous implant technologies from Biomet and Canary Medical to measure and determine range of motion, gait speed, step count, walking speed and other measurements. The implant allows patients who underwent joint replacement to access their mobility data and surgeons to monitor patient recovery.
“Zimmer Biomet has a strong heritage of delivering revolutionary innovations that can transform the surgical experience and enable data-supported patient care,” Ivan Tornos, chief operating officer of Zimmer Biomet, said in the release. “The postoperative data captured by Persona IQ, together with the wealth of pre[operative] and postoperative data collected by the mymobility platform, will provide surgeons with an exceptional level of objective and comparative data intelligence.”
According to the release, Persona IQ delivers patient gait data to a cloud-based platform, allowing surgeons to compare preoperative mobility metrics captured by mymobility with postoperative gait metrics. Persona IQ does not rely on patient compliance, according to the release, and passively collects data with a battery that lasts up to 10 years. Persona IQ will be available to health care professionals and patients in the coming months.